Результаты поиска

Использование и управление аптеками, принадлежащими страховщикам и управляющими пособиями в области фармацевтики в Медикаре.

IMORTANS: Все большую озабоченность в области нормативного регулирования вызывает преобладание аптек, принадлежащих интегрированным страховщикам и менеджерам по выплате пособий по аптекам (УБМ), или страховщикам-УПМ. Однако мало что известно о роли этих аптек в Медикаре, где защита сети аптек может повлиять на динамику рынка. ЦЕЛЬ: Оценить распространенность аптек, принадлежащих страховщикам, и степень, в которой страховщики-ПБР направляют пациентов в аптеки, которыми они владеют в Медикаре. DESIGN, SETTING, И УЧАСТНИКИ: В рамках этого межсекторального исследования использовались данные о прет

Совпадение в полном тексте источника
… For example, for CVS and atorvastatin, we identified (1) the share of atorvastatin claims in CVS Part D plans filled by CVS-owned pharmacies and (2) the share of atorvastatin claims in non-CVS Part D plans filled by CVS-owned pharmacies. …

Statins for the primary prevention of venous thromboembolism.

BACKGROUND: Venous thromboembolism (VTE) involves the formation of a blood clot in a vein, and includes deep venous thrombosis (DVT) or pulm … bo or usual care in individuals who had never experienced VTE. The statins used in the studies were atorvastatin, rosuvastatin, pravastatin, lovastatin, fluvastatin, and simvastatin. Twenty-three studies followed up participants for over a year, with six of those extending follow-ups for over five years. Twenty-five studies were based in hospitals, and 24 stud …

AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY GUIDELINES FOR MANAGEMENT OF DYSLIPIDEMIA AND PREVENTION OF CARDIOVASCULAR DISEASE.

OBJECTIVE: The development of these guidelines is mandated by the American Association of Clinical Endocrinologists (AACE) Board of Director … index CABG = coronary artery bypass graft CAC = coronary artery calcification CARDS = Collaborative Atorvastatin Diabetes Study CDP = Coronary Drug Project trial CI = confidence interval CIMT = carotid intimal media thickness CKD = chronic kidney disease CPG(s) = clinical practice guideline(s) CRP = C-reactive protein CTT = Cholesterol Treatment Trialists CV = …

Patterns of Statin Use in a Real-World Population of Patients at High Cardiovascular Risk.

BACKGROUND: Widespread use of statins has improved hypercholesterolemia management, yet a significant proportion of patients remain at risk … ent visit during the follow-up period. Statin therapy was subdivided into high-intensity treatment (atorvastatin 40 mg or 80 mg, rosuvastatin 20 mg or 40 mg, or simvastatin 80 mg) or moderate- to low-intensity treatment (all other statins and statin dosing regimens). Follow-up data were obtained from the index date (statin initiation) until the end of continuo …

Statins: a repurposed drug to fight cancer.

As competitive HMG-CoA reductase (HMGCR) inhibitors, statins not only reduce cholesterol and improve cardiovascular risk, but also exhibit pleiotropic effects that are independent of their lipid-lowering effects. Among them, the anti-cancer properties of statins have attracted much attention and indicated the potential of statins as repurposed drugs for the treatment of cancer. A large number of clinical and epidemiological studies have described the anticancer properties of statins, but the evidence for anticancer effectiveness of statins is inconsistent. It may be that certain molecular subt

Совпадение в полном тексте источника
… | In vitro | 0–50 μM | Irradiation | Atorvastatin enhances the radiosensitivity of hypoxia-induced prostate cancer cells by decreasing the expression of HIF-1α protein | [ 84 ] Atorvastatin | In vitro | 0–5 μM | Caffeine | The combination of atorvastatin and caffeine suppressed proliferation and induced … Atorvastatin stimulates autophagy in human umbilical vein endothelial cells. Furthermore, high-dose atorvastatin activates apoptosis and inhibits angiogenesis. …

A comprehensive evaluation of potentially significant drug-drug, drug-herb, and drug-food interactions among cancer patients receiving anticancer drugs.

IntroductionDuring the cancer treatment path, cancer patients use numerous drugs, including anticancer, supportive, and other prescribed medications, along with herbs and certain products. This puts them at risk of significant drug interactions (DIs). This study describes DIs in cancer patients and their prevalence and predictors.MethodsA cross-sectional study design was used to achieve the study objectives. The study was carried out in two centers in the northern West Bank, Palestine. The Lexicomp® Drug Interactions tool (Lexi-Comp, Hudson OH, USA) was applied to check the potential DIs. In a

Совпадение в полном тексте источника
… The most common interactions were Dexamethasone/Grapefruit, Prednisolone/Grapefruit, Paclitaxel/Grapefruit, Atorvastatin/Grapefruit, and Amlodipine/Grapefruit (Table 6 ). However, the combination that should be avoided ‘X’ was Aprepitant/Grapefruit ( n = 8). … /Grapefruit | 11 | D | Grapefruit may increase the serum concentration of atorvastatin Amlodipine/Grapefruit | 11 | B | Grapefruit may increase the serum concentration of amlodipine Univariate and multivariate analysis of potential DDIs Univariate analysis showed a significant association between the …

Pharmaceutical Prevention and Management of Cardiotoxicity in Hematological Malignancies.

Modern treatment modalities in hematology have improved clinical outcomes of patients with hematological malignancies. Nevertheless, many new or conventional anticancer drugs affect the cardiovascular system, resulting in various cardiac disorders, including left ventricular dysfunction, heart failure, arterial hypertension, myocardial ischemia, cardiac rhythm disturbances, and QTc prolongation on electrocardiograms. As these complications may jeopardize the significantly improved outcome of modern anticancer therapies, it is crucial to become familiar with all aspects of cardiotoxicity and pr

Совпадение в полном тексте источника
… In patients without preexisting cardiovascular abnormalities, the administration of 40 mg atorvastatin daily led to the preservation of LVEF [ 86 ]. … However, the recently published randomized, placebo-controlled pilot clinical trial, examining the effect of atorvastatin on vascular function and structure in young adult survivors of childhood cancer showed that six months of atorvastatin treatment did not ameliorate endothelial function or arterial …

Rhabdomyolysis secondary to COVID-19 infection and vaccination: a review of literature.

Rhabdomyolysis (RML), characterized by the breakdown of skeletal muscle fibers and the release of muscle contents into the bloodstream, has emerged as a notable complication associated with Coronavirus disease 2019 (COVID-19) infection and vaccination. Studies have reported an increased incidence of RML in individuals with severe COVID-19 infection. However, the exact mechanisms remain unclear and are believed to involve the host's immune response to the virus. Furthermore, RML has been documented as a rare adverse event following COVID-19 vaccination, particularly with mRNA vaccines. Proposed

Совпадение в полном тексте источника
… The patient was on Atorvastatin 40 mg with positive past myotoxic DH. Lab results revealed a peak CK of 6,164, LDH of 624, and creatinine of 24.3. … The patient was on Atorvastatin 20 mg, Metformin with positive past myotoxic DH. Lab results revealed a peak CK of 4,625, LDH of 845 and creatinine of 24.3. …

[Sex, erectile dysfunction, and the heart: a growing problem].

BACKGROUND: Erectile dysfunction (ED) is defined as the inability to attain and/or maintain penile erection sufficient for satisfactory sexu … ntrations of sildenafil, like cimetidine, erythromycin, digitoxin, and CSE inhibitors (simvastatin, atorvastatin, etc.). A creatinine clearance < 30 ml/min also increases plasma levels of sildenafil. SAFETY PROFILE OF SILDENAFIL: Sildenafil is safe in healthy subjects. In a postmarketing study on 6,527 males, no increase of cardiovascular events was found. Ho …

[Update cardiology 2001/2002-part II. From unstable coronary syndrome to terminal heart failure].

The cardiovascular continuum describes the way from risk factors to atherosclerosis, acute cardiovascular events (unstable angina and myocardial infarction), and development of terminal heart failure and its complications. Following this way, advances are reported in the therapy of acute coronary syndrome, heart failure, ventricular and supraventricular tachyarrhythmias, and stroke in patients with patent foramen ovale. The following issues are reported in detail: (1) significance of statins and statin withdrawal, glycoprotein IIb/IIIa receptor blocker, acute coronary interventions, aspirin an

Purinergic receptor-mediated rapid depletion of nuclear phosphorylated Akt depends on pleckstrin homology domain leucine-rich repeat phosphatase, calcineurin, protein phosphatase 2A, and PTEN phosphatases.

Akt is an important oncoprotein, and data suggest a critical role for nuclear Akt in cancer development. We have previously described a rapid (3-5 min) and P2X7-dependent depletion of nuclear phosphorylated Akt (pAkt) and effects on downstream targets, and here we studied mechanisms behind the pAkt depletion. We show that cholesterol-lowering drugs, statins, or extracellular ATP, induced a complex and coordinated response in insulin-stimulated A549 cells leading to depletion of nuclear pAkt. It involved protein/lipid phosphatases PTEN, pleckstrin homology domain leucine-rich repeat phosphatase

Тенденции сокращения потребления липидов, интенсивности лечения и целевого показателя ЛДЛ-С для взрослых, страдающих диабетом и хроническими заболеваниями почек, не связанными с диализом в Гонконге.

С учетом меняющихся целевых показателей лечения, обеспокоенности по поводу почечной безопасности некоторых статинов и новых липидовых лекарственных средств (ЛЛД) мы стремились оценить тренды статинов и нестатичных ЛЛД [изетимибе и пропротеиновой трансформазы субтилизины/кексина типа 9 PCSK9i)] использование в Гонконге у лиц с диабетом и хроническими заболеваниями почек, не связанными с диализом (CKD). МЕТОДЫ: Мы провели ретроспективное когортное исследование 332,975 Китайские лица, страдающие диабетом и недиализом CKD, используя данные Управления больниц Гонконга 2002-2019. Мы проанализировали

Совпадение в полном тексте источника
… The cost per defined daily dose (DDD) is approximately HKD 0.2 (USD 0.03) for generic simvastatin, rosuvastatin and atorvastatin. … In our cohort, majority of individuals with diabetes and CKD were on low-to-moderate-intensity simvastatin or atorvastatin monotherapy. Only 6% were on high-dose atorvastatin or rosuvastatin. …

Network Pharmacology Approaches Used to Identify Therapeutic Molecules for Chronic Venous Disease Based on Potential miRNA Biomarkers.

Chronic venous disease (CVD) is a prevalent condition in adults, significantly affecting the global elderly population, with a higher incidence in women than in men. The modulation of gene expression through microRNA (miRNA) partly regulated the development of cardiovascular disease (CVD). Previous research identified a functional analysis of seven genes (CDS2, HDAC5, PPP6R2, PRRC2B, TBC1D22A, WNK1, and PABPC3) as targets of miRNAs related to CVD. In this context, miRNAs emerge as essential candidates for CVD diagnosis, representing novel molecular and biological knowledge. This work aims to i

Совпадение в полном тексте источника
… The effect of atorvastatin, 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitor (HMG-CoA), on the prevention of osteoporosis in ovariectomized rabbits J. Bone Miner. Metab. 2017 35 245 254 10.1007/s00774-016-0750-2 27119523 71. Jiang Y. Shen X. Zhi F. Wen Z. Gao Y. Xu J. Yang B. Bai Y. … | 46780495 | 0.212 | 12 | 0.013398551 | HMG-CoA reductase inhibitor Atorvastatin, (3S,5R)- | 6093359 | 0.212 | 10 | 0.007799482 | HMG-CoA reductase inhibitor ent-Atorvastatin | 62976 | 0.212 | 7 | 0.002740719 | HMG-CoA reductase inhibitor Atorvastatin | 60823 | 0.212 | 12 | 0.013398551 | HMG-CoA reductase …

Statins Enhance the Molecular Response in Chronic Myeloid Leukemia when Combined with Tyrosine Kinase Inhibitors.

Previous studies have suggested that statins can be repurposed for cancer treatment. However, the therapeutic efficacy of statins in chronic myeloid leukemia (CML) has not yet been demonstrated. In this study, we retrospectively evaluated the outcomes of 408 CML patients who underwent imatinib therapy. The deep molecular response rates in patients treated with the statin/TKI combination were significantly higher than those in patients treated with TKI alone (p = 0.0016). The statin/TKI combination exerted potent cytotoxic effects against wild-type and ABL1 mutant CML, BaF3, and K562/T315I muta

Совпадение в полном тексте источника
… The statins administered were atorvastatin ( n = 44, 50%), rosuvastatin ( n = 26, 30%), simvastatin ( n = 10, 11%), pravastatin ( n = 6, 7%), and fluvastatin ( n = 2, 2%). … Atorvastatin and simvastatin, but not rosuvastatin and fluvastatin, are metabolized by CYP3A4/3A5 [ 43 , 44 ]. Thus, two different types of statins (rosuvastatin and atorvastatin) were analyzed ( Figure 3 ). …

Strategies to Mitigate Cisplatin-Induced Ototoxicity: A Literature Review of Protective Agents, Mechanisms, and Clinical Gaps.

BackgroundCisplatin, a widely used chemotherapeutic agent, is associated with significant ototoxicity, leading to progressive and irreversible sensorineural hearing loss in up to 93% of patients. Cisplatin generates reactive oxygen species (ROS) in the cochlea, activating apoptotic and necroptotic pathways that result in hair cell death. Inflammatory processes and nitrative stress also contribute to cochlear damage.MethodsThis literature review was conducted to explore the mechanisms underlying cisplatin-induced ototoxicity and evaluate protective strategies, including both current and emergin

Совпадение в полном тексте источника
… Atorvastatin users experienced a significantly lower incidence of hearing loss (9.7%) compared to non-statin users (29.4%) during cisplatin treatment, further supporting statins’ potential role in otoprotection [ 93 ]. … Randomized, Placebo-Controlled Trial of Atorvastatin to Prevent Hearing Loss in Patients with Head and Neck Squamous Cell Carcinoma Receiving Cisplatin Based Chemoradiation (CRT) JCO. 2024;42:TPS12153. doi: 10.1200/JCO.2024.42.16_suppl.TPS12153. 93. …

Recent trends in specialty pharma business model.

The recent rise of specialty pharma is attributed to its flexible, versatile, and open business model while the traditional big pharma is facing a challenging time with patent cliff, generic threat, and low research and development (R&D) productivity. These multinational pharmaceutical companies, facing a difficult time, have been systematically externalizing R&D and some even establish their own corporate venture capital so as to diversify with more shots on goal, with the hope of achieving a higher success rate in their compound pipeline. Biologics and clinical Phase II proof-of-concept (POC

Совпадение в полном тексте источника
… Lipitor: the biggest generic entry in history The patent on Lipitor (atorvastatin calcium tablet), Pfizer’s $12 billion-a-year blockbuster cholesterol medicine with lifetime sales of > $131 billion, expired on 29 November, 2011. … After Ranbaxy’s 180-day exclusivity period ended on May 31, 2012, other generic manufacturers’ versions of atorvastatin entered the market, and atorvastatin’s price dropped dramatically. The May 2012 date is not incidental. …

Opportunities and Challenges of Small Molecule Induced Targeted Protein Degradation.

Proteolysis targeting chimeras (PROTAC) represents a new type of small molecule induced protein degradation technology that has emerged in recent years. PROTAC uses bifunctional small molecules to induce ubiquitination of target proteins and utilizes intracellular proteasomes for chemical knockdown. It complements the gene editing and RNA interference for protein knockdown. Compared with small molecule inhibitors, PROTAC has shown great advantages in overcoming tumor resistance, affecting the non-enzymatic function of target proteins, degrading undruggable targets, and providing new rapid and

Совпадение в полном тексте источника
… A series of small degraders were designed and synthesized based on atorvastatin as the target ligand and Pomalidomide and Lenalidomide as E3 ligands. … In contrast, the inhibitor atorvastatin caused a significant upregulation of HMGCR. Besides, proteomics analysis found that the omics responses caused by the inhibitors atorvastatin and compound P22A were also very different. …

Ангина из-за обструкционистской болезни коронарной артерии в сочетании с периферической болезнью артерии.

Аннотация не предоставлена источником. Откройте карточку для перехода к публикации.

Совпадение в полном тексте источника
… His was on aspirin 100 mg once daily, atorvastatin 20 mg once daily, ramipril 5 mg once daily, and metformin 1000 mg twice daily. His blood pressure was 145/90 mmHg and heart rate was 90 b.p.m. at admission. … The atorvastatin dosage was also increased to 40 mg once daily, and the patient was included in a smoking cessation programme. 1 Figure 1 ( A ) Coronary angiography showed the left anterior descending, circumflex and right coronary arteries. …

An actionable sterol-regulated feedback loop modulates statin sensitivity in prostate cancer.

ObjectiveThe statin family of cholesterol-lowering drugs has been shown to induce tumor-specific apoptosis by inhibiting the rate-limiting enzyme of the mevalonate (MVA) pathway, HMG-CoA reductase (HMGCR). Accumulating evidence suggests that statin use may delay prostate cancer (PCa) progression in a subset of patients; however, the determinants of statin drug sensitivity in PCa remain unclear. Our goal was to identify molecular features of statin-sensitive PCa and opportunities to potentiate statin-induced PCa cell death.MethodsDeregulation of HMGCR expression in PCa was evaluated by immunohi

Совпадение в полном тексте источника
… For example, in breast cancer, high basal expression of sterol biosynthesis genes has been associated with resistance to atorvastatin [22] . … Fluvastatin quantification Fluvastatin concentrations were quantified by high-performance liquid chromatography (HPLC)-tandem mass spectrometry (MS/MS) with atorvastatin used as the internal standard. …

Доклад по делу: Воспаление фенотипа CADASIL, связанного с редким вариантом NoTHH3.

Мы представляем 50-летнюю женщину, которая имеет давнюю историю мигрени с аурой. Она пережила один эпизод частичной потери визуального поля, связанный с небольшим острым/субочное повреждением коры и субкортической белой материи (показание контрастного усиления), наряду с обширной гиперинтенсивностью белой материи. Исходя из этих выводов, КАДАСИЛ был подозреваем. Генетические тесты выявили редкий гетероговый вариант NETCH3 (c.6102dup, p.Gly2035Argfs*60), который в настоящее время классифицируется как вариант неопределенного значения. Анализ конъюнктурной цереброспинарной жидкости показал повыше

Совпадение в полном тексте источника
… She is currently managed with aspirin, cilostazol, and atorvastatin for secondary stroke prevention, and verapamil as a migraine prophylaxis medication, significantly reducing both the frequency and severity of her migraines ( Figure 1 ). … As of November 2024, our patient is effectively managed with dual antiplatelet therapy (aspirin and cilostazol), atorvastatin for secondary stroke prevention, and verapamil for migraine prophylaxis ( Figure 1 ). Her neurological exam remains stable, with complete resolution of visual symptoms. …